Oncolytics Biotech Stock Performance

ONC Stock  CAD 1.53  0.08  4.97%   
Oncolytics Biotech holds a performance score of 13 on a scale of zero to a hundred. The company holds a Beta of -1.6, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Oncolytics Biotech are expected to decrease by larger amounts. On the other hand, during market turmoil, Oncolytics Biotech is expected to outperform it. Use Oncolytics Biotech maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to analyze future returns on Oncolytics Biotech.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Oncolytics Biotech are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Oncolytics Biotech displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor
105:1000
Dividend Date
2018-05-25
Last Split Date
2018-05-25
1
Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights - Yahoo Finance
05/06/2025
2
Oncolytics Biotech Downgraded by Jones Trading ONCY Sto - GuruFocus
05/16/2025
3
Proactive Strategies - news.stocktradersdaily.com
05/27/2025
4
After Major Oncology Conference, All Eyes Turn to Industry Innovation - Morningstar
06/12/2025
5
Top Steel Picks for the Coming Infrastructure Boom - The Globe and Mail
06/25/2025
6
Pelareorep A Breakthrough in Oncolytics Biotechs Fight Against Pancreatic and Breast Cancers A High-Conviction Buy at Current Levels - AInvest
07/09/2025
7
Cancer Treatment Breakthrough How This Drug Transforms Cold Tumors into Hot, Fighting Multiple Cancer Types - Stock Titan
07/16/2025
8
What drives Oncolytics Biotech Inc. stock price - Superior trading gains - PrintWeekIndia
07/24/2025
Begin Period Cash Flow34.9 M
Total Cashflows From Investing Activities-239 K
  

Oncolytics Biotech Relative Risk vs. Return Landscape

If you would invest  77.00  in Oncolytics Biotech on April 26, 2025 and sell it today you would earn a total of  76.00  from holding Oncolytics Biotech or generate 98.7% return on investment over 90 days. Oncolytics Biotech is generating 1.4202% of daily returns assuming 8.2623% volatility of returns over the 90 days investment horizon. Simply put, 74% of all stocks have less volatile historical return distribution than Oncolytics Biotech, and 72% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days trading horizon Oncolytics Biotech is expected to generate 10.5 times more return on investment than the market. However, the company is 10.5 times more volatile than its market benchmark. It trades about 0.17 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.22 per unit of risk.

Oncolytics Biotech Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncolytics Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncolytics Biotech, and traders can use it to determine the average amount a Oncolytics Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1719

Best PortfolioBest Equity
Good Returns
Average ReturnsONC
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 8.26
  actual daily
74
74% of assets are less volatile

Expected Return

 1.42
  actual daily
28
72% of assets have higher returns

Risk-Adjusted Return

 0.17
  actual daily
13
87% of assets perform better
Based on monthly moving average Oncolytics Biotech is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncolytics Biotech by adding it to a well-diversified portfolio.

Oncolytics Biotech Fundamentals Growth

Oncolytics Stock prices reflect investors' perceptions of the future prospects and financial health of Oncolytics Biotech, and Oncolytics Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncolytics Stock performance.

About Oncolytics Biotech Performance

By examining Oncolytics Biotech's fundamental ratios, stakeholders can obtain critical insights into Oncolytics Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Oncolytics Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.57)(1.65)
Return On Capital Employed(2.59)(2.46)
Return On Assets(1.57)(1.65)
Return On Equity(5.30)(5.04)

Things to note about Oncolytics Biotech performance evaluation

Checking the ongoing alerts about Oncolytics Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncolytics Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Oncolytics Biotech is way too risky over 90 days horizon
Oncolytics Biotech may become a speculative penny stock
Oncolytics Biotech appears to be risky and price may revert if volatility continues
Net Loss for the year was (31.71 M) with profit before overhead, payroll, taxes, and interest of 0.
Oncolytics Biotech has accumulated about 3.63 M in cash with (26.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72.
Latest headline from news.google.com: What drives Oncolytics Biotech Inc. stock price - Superior trading gains - PrintWeekIndia
Evaluating Oncolytics Biotech's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Oncolytics Biotech's stock performance include:
  • Analyzing Oncolytics Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncolytics Biotech's stock is overvalued or undervalued compared to its peers.
  • Examining Oncolytics Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Oncolytics Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncolytics Biotech's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Oncolytics Biotech's stock. These opinions can provide insight into Oncolytics Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Oncolytics Biotech's stock performance is not an exact science, and many factors can impact Oncolytics Biotech's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.